Epic Sciences

Select Publications

04.26.2017

Cellular expression of PD-L1 in the peripheral blood of lung cancer patients is associated with worse survival.

Boffa, D et al. Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. 2017 January. DOI: 10.1158/1055-9965.EPI-17-0120

12.14.2017

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.

Anantharaman, A et al. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Cancer 201616:744 DOI: 10.1186/s12885-016-2758-3

11.24.2016

Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer.

Scher, H et al. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. 2016 November. DOI:/10.1016/j.eururo.2016.11.024

09.18.2016

Phenotypic diversity of circulating tumor cells in patients with metastatic castration-resistant prostate cancer.

McDaniel AS, et al. Phenotypic diversity of circulating tumor cells in patients with metastatic castration-resistant prostate cancer. BJU Int. 2016 Aug . doi: 10.1111/bju.13631. [Epub ahead of print]

09.08.2016

Circulating tumor cells (CTC) and cell-free DNA (cfDNA) workshop 2016: Scientific opportunities and logistics for cancer clinical trial incorporation.

Lowes, LE et al. Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation. Int J Mol Sci. 2016 Sep ;17(9)

06.04.2016

Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer.

Scher, H et al. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA Oncology. Advance Online Publication: 2016 June. DOI:10.1001/jamaoncol.2016.1828

03.15.2016

The initial detection and partial characterization of circulating tumor cells in neuroendocrine prostate cancer.

Beltran, H et al. The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. 2016 March. DOI:10.1158/1078-0432.CCR-15-0137